SEC Form 4 · accession 0001179110-17-004592
ACCELERON PHARMA INC · XLRN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Ravindra Kumar
Officer — SVP & Chief Scientific Officer
Period of report
Mar 2, 2017
Accepted (ET)
Mar 14, 2017 · 6:17 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001280600
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Mar 2, 2017 | A | 6,900 | $0.00 | A | 95,327 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Option to Purchase Common StockF1 | $30.17 | Mar 2, 2017 | A | 41,300 | A | — | Mar 2, 2027 | Common Stock | 41,300 | 41,300 | D |
Explanation of responses
- F1The shares of common stock underlying this stock option award vest in equal quarterly installments over the four years after January 1, 2017.